Analysts Offer Predictions for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 1st. Brookline Capital Management analyst K. Raja anticipates that the company will earn ($0.15) per share for the quarter. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics' Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at $0.14 EPS.

Separately, HC Wainwright raised their price objective on Unicycive Therapeutics from $4.00 to $7.50 and gave the company a "buy" rating in a research report on Tuesday, April 1st.

Unicycive Therapeutics Price Performance

NASDAQ UNCY traded up $0.02 during midday trading on Thursday, hitting $0.48. 412,526 shares of the company traded hands, compared to its average volume of 1,434,843. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.45. The company's 50-day simple moving average is $0.58 and its 200-day simple moving average is $0.58. The company has a market cap of $57.10 million, a PE ratio of -0.49 and a beta of 2.15.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13).

Institutional Trading of Unicycive Therapeutics

Institutional investors have recently bought and sold shares of the stock. Northern Trust Corp raised its holdings in shares of Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after buying an additional 34,183 shares during the last quarter. Virtu Financial LLC lifted its position in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after acquiring an additional 62,881 shares during the period. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics during the 3rd quarter worth about $29,000. Geode Capital Management LLC grew its stake in Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC increased its holdings in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after purchasing an additional 323,801 shares during the period. 40.42% of the stock is currently owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.